Ten shares become one; ownership percentages are otherwise unchanged, with cash replacing fractional shares.
Onconetix, Inc. (ONCO) announced a 1-for-10 reverse stock split, effective November 6, 2026. Outstanding shares will reduce from ~5.89M to ~588.68K, with cash for fractional shares. Trading continues under 'ONCO' on Nasdaq. Ownership percentages remain unchanged.
How this was made
The 30-second read
Why it matters
The reverse split is a corporate restructuring action with limited immediate financial impact but may affect share liquidity and price perception.
Market read
Primary relevance is to ONCO shareholders; broader market effect is minimal.
What to watch
Potential dilution from future equity raises or conversion of warrants could offset any price benefit.
Background
Onconetix is a commercial‑stage biotech focused on oncology diagnostics, listed on Nasdaq under ONCO.
Ticker impact
Onconetix announced a 1-for-10 reverse stock split effective Nov 6, 2026, changing share count and cash for fractions.
potential modest upside as price per share rises post‑split, but limited by unchanged fundamentals
Reverse splits often lead to short‑term price adjustments; no fundamental change, so impact is limited.
Market effects
May slightly improve biotech sector perception of listed micro‑caps seeking higher share price.
Limited to US biotech investors; no broader regional effect.
Minimal global impact; primarily affects existing ONCO shareholders.
Counterpoint
Reverse splits can be a red flag of low liquidity; investors may stay cautious.
Key entities
- CompanyOnconetix, Inc.
Biotech firm executing a 1‑for‑10 reverse stock split.
